Day: May 29, 2025

NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder

Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is...

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in...

error: Content is protected !!